Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The New Out-Licensing Start-Ups: Securing Product Supply

This article was originally published in Start Up

Executive Summary

A new crop of companies deals head-on with Big Pharma's biggest out-licensing problems--transaction cost and the "embarrassment factor." Solving both involves strategies to make the extra work of out-licensing worthwhile for their large partners. In particular, after years of resisting the idea, they're now allowing their Big Pharma partners the right to buy back the compounds, usually after clinical proof of concept.

Related Content

Corporate VC Adds a Business Development Flavor
Lilly's Chorus Experiment
Synosis: the Financial Leverage of Translational Medicine
The A-List: 2006's Trend-Shaping Series A Financings
Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma
GSK's Risk-Sharing Deals to Compete with In-House R&D
ViroPharma's Second Act: First a Tough One to Follow
Jumpstarting Research: Big Pharma's Out-Licensing Dilemma
Jumpstart to Products
In-Licensing: Still a Difficult Model


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts